TFX logo

Teleflex Incorporated Stock Price

NYSE:TFX Community·US$5.9b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 16 Fair Values set on narratives written by author

TFX Share Price Performance

US$135.73
19.33 (16.61%)
US$143.67
Fair Value
US$135.73
19.33 (16.61%)
5.5% undervalued intrinsic discount
US$143.67
Fair Value
Price US$135.73
AnalystConsensusTarget US$143.67
AnalystHighTarget US$160.00
AnalystLowTarget US$135.00

TFX Community Narratives

·
Fair Value US$143.67 5.5% undervalued intrinsic discount

Acquisitions And Asian Expansion Will Broaden Healthcare Horizons

0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
·
Fair Value US$160 15.2% undervalued intrinsic discount

Aging Populations And Emerging Markets Will Transform Medical Devices

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
·
Fair Value US$135 0.5% overvalued intrinsic discount

Rising Cost Pressures And Supply Risks Will Shrink Healthcare Prospects

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$160
15.2% undervalued intrinsic discount
Revenue
6.97% p.a.
Profit Margin
10.15%
Future PE
33.84x
Price in 2029
US$200.97
US$135
0.5% overvalued intrinsic discount
Revenue
6.34% p.a.
Profit Margin
10.07%
Future PE
29.36x
Price in 2029
US$169.93
US$143.67
5.5% undervalued intrinsic discount
Revenue
6.23% p.a.
Profit Margin
11.65%
Future PE
27.06x
Price in 2029
US$180.65

Trending Discussion

Updated Narratives

TFX logo

TFX: Biotronik Synergies And Portfolio Separation Will Reshape Earnings Profile

Fair Value: US$160 15.2% undervalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
TFX logo

TFX: Biotronik Synergies And Activist Pressure Will Shape Execution Risk Going Forward

Fair Value: US$135 0.5% overvalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
TFX logo

TFX: Portfolio Reset And Recent Upgrades Will Shape Balanced Forward Outlook

Fair Value: US$143.67 5.5% undervalued intrinsic discount
8 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Fair value with moderate growth potential.

3 Risks
2 Rewards

Teleflex Incorporated Key Details

US$2.1b

Revenue

US$950.0m

Cost of Revenue

US$1.2b

Gross Profit

US$1.2b

Other Expenses

US$1.4m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
0.031
55.33%
0.064%
86.6%
View Full Analysis

About TFX

Founded
1943
Employees
15500
CEO
Jason Weidman
WebsiteView website
www.teleflex.com

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company offers vascular and emergency medicine products comprising Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous bone access systems for the administration of intravenous therapies, measurement of blood pressure, and collection of blood samples; intraosseous access systems consisting of EZ-IO intraosseous vascular access systems, and Arrow FAST1 sternal intraosseous infusion systems; and hemostatic products, including external hemostats and trauma products under the QuikClot brand. It also provides interventional products, including various coronary catheters, structural heart support devices, and peripheral intervention products platforms; GuideLiner, Turnpike, and TrapLiner catheters; MANTA vascular closure devices and Arrow OnControl powered bone biopsy systems; and coronary and peripheral medical devices, such as drug-coated balloons, stents, and balloon catheters. In addition, the company offers surgical products, including metal and polymer ligating clips using manual and automatic applier system, fascial closure surgical systems used in laparoscopic surgical procedures, percutaneous surgical systems, powered bariatric staplers, and other surgical instruments under the Weck, MiniLap, Pleur-Evac, Deknatel, KMedic, Pilling, and Titan SGS brands. It serves hospitals, healthcare providers, and medical device manufacturers. The company also sells its products online. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

Recent TFX News & Updates

Narrative Update Jul 07

TFX: Biotronik Synergies And Portfolio Separation Will Reshape Earnings Profile

Analysts have lifted their fair value estimate for Teleflex stock from $155 to $160 as they factor in potential benefits from Biotronik-related synergies, capital deployment that is still filtering into Street models, and possible value creation linked to activist involvement. Analyst Commentary Recent research updates around Teleflex highlight a more constructive tone from bullish analysts, with several price target revisions and rating changes aligning around the new US$160 fair value estimate.
Narrative Update Jun 22

TFX: Biotronik Synergies And Activist Pressure Will Shape Execution Risk Going Forward

Analysts have raised the fair value estimate for Teleflex stock from $116.81 to $135.00, reflecting updated assumptions around capital deployment, Biotronik-related synergies, potential activist-driven value creation, and a slightly higher future P/E multiple. Analyst Commentary Recent Street research on Teleflex has focused on how potential Biotronik synergies, capital deployment plans, and possible activist involvement could influence the stock's risk and reward profile.

Recent updates

No updates